Phase Ib/II Study of a Liposomal Formulation of Eribulin (E7389-LF) plus Nivolumab in Patients with Advanced Solid Tumors: Results from Phase Ib

PURPOSE: To determine a recommended dose of liposomal eribulin (E7389-LF) in combination with nivolumab in patients with advanced solid tumors, and to evaluate the safety, efficacy, pharmacokinetics, and biomarker impact of this regimen. EXPERIMENTAL DESIGN: Japanese patients with advanced, nonresec...

Descripción completa

Detalles Bibliográficos
Autores principales: Ida, Hanae, Shimizu, Toshio, Nishino, Makoto, Nakamura, Yoshiaki, Yazaki, Shu, Katsuya, Yuki, Sato, Jun, Koyama, Takafumi, Iwasa, Satoru, Sudo, Kazuki, Kondo, Shunsuke, Yonemori, Kan, Shitara, Kohei, Shiono, Satoshi, Matsuoka, Daiko, Yasuda, Keisuke, Otake, Yohei, Suzuki, Takuya, Takase, Takao, Takashima, Shuya, Yamaguchi, Kohei, Semba, Taro, Yamamoto, Noboru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10332326/
https://www.ncbi.nlm.nih.gov/pubmed/37435605
http://dx.doi.org/10.1158/2767-9764.CRC-22-0401

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10332326/
https://www.ncbi.nlm.nih.gov/pubmed/37435605
http://dx.doi.org/10.1158/2767-9764.CRC-22-0401

Ejemplares similares